MRSN has been the topic of several other research reports. Zacks Investment Research raised shares of Mersana Therapeutics from a sell rating to a hold rating in a report on Thursday, January 11th. JPMorgan Chase downgraded shares of Mersana Therapeutics from an overweight rating to a neutral rating and set a $23.00 target price on the stock. in a report on Monday, March 19th. ValuEngine raised shares of Mersana Therapeutics from a strong sell rating to a sell rating in a report on Friday, February 2nd. Cowen reissued a buy rating on shares of Mersana Therapeutics in a report on Monday. Finally, Leerink Swann reissued an outperform rating on shares of Mersana Therapeutics in a report on Wednesday, March 28th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $24.80.
MRSN stock opened at $16.84 on Tuesday. Mersana Therapeutics has a one year low of $12.45 and a one year high of $21.01. The firm has a market capitalization of $378.56 and a PE ratio of -5.23.
A number of institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. raised its stake in Mersana Therapeutics by 11.0% during the fourth quarter. Victory Capital Management Inc. now owns 57,930 shares of the company’s stock valued at $952,000 after purchasing an additional 5,730 shares in the last quarter. Geode Capital Management LLC raised its stake in Mersana Therapeutics by 10.1% during the fourth quarter. Geode Capital Management LLC now owns 63,173 shares of the company’s stock valued at $1,037,000 after purchasing an additional 5,821 shares in the last quarter. TIAA CREF Investment Management LLC raised its stake in Mersana Therapeutics by 1,132.7% during the fourth quarter. TIAA CREF Investment Management LLC now owns 8,037 shares of the company’s stock valued at $132,000 after purchasing an additional 7,385 shares in the last quarter. California State Teachers Retirement System purchased a new stake in Mersana Therapeutics during the third quarter valued at $142,000. Finally, Candriam Luxembourg S.C.A. purchased a new stake in Mersana Therapeutics during the fourth quarter valued at $197,000. 75.43% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “HC Wainwright Analysts Give Mersana Therapeutics (MRSN) a $33.00 Price Target” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://weekherald.com/2018/04/20/hc-wainwright-analysts-give-mersana-therapeutics-mrsn-a-33-00-price-target.html.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.